206 related articles for article (PubMed ID: 25713719)
1. Peritoneal tuberculosis presenting as recurrent peritonitis secondary to treatment with intravesical Bacillus Calmette-Guérin in a patient receiving peritoneal dialysis.
Iqbal J; Raja M; Leung J
Clin Kidney J; 2015 Feb; 8(1):107-8. PubMed ID: 25713719
[TBL] [Abstract][Full Text] [Related]
2. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
Hudson MA; Yuan JJ; Catalona WJ; Ratliff TL
J Urol; 1990 Dec; 144(6):1362-4. PubMed ID: 2231927
[TBL] [Abstract][Full Text] [Related]
3. Miliary tuberculosis following intravesical Bacillus Calmette and Guérin therapy: A rare complication of a frequent procedure.
Loued L; Fahem N; Kaddoussi R; Abdelaaly M; Cheikh Mhamed S; Rouatbi N
Urol Case Rep; 2021 Sep; 38():101655. PubMed ID: 33868941
[TBL] [Abstract][Full Text] [Related]
4. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors.
Kavoussi LR; Torrence RJ; Gillen DP; Hudson MA; Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
J Urol; 1988 May; 139(5):935-40. PubMed ID: 3361667
[TBL] [Abstract][Full Text] [Related]
5. A case of infectious thoracic aortic aneurysm after intravesical Bacillus Calmette-Guérin instillation therapy for a superficial bladder cancer.
Koterazawa S; Watanabe J; Uemura Y; Uegaki M; Shirahase T; Taki Y
Urol Case Rep; 2021 May; 36():101574. PubMed ID: 33552915
[TBL] [Abstract][Full Text] [Related]
6. [Classification, favorable characteristics, prevention and treatment of adverse side-effects associated with Bacillus Calmette-Guerin in the treatment of superficial bladder cancer].
Saint F; Salomon L; Quintela R; Cicco A; Abbou CC; Chopin DK
Ann Urol (Paris); 2002 Mar; 36(2):120-31. PubMed ID: 11969046
[TBL] [Abstract][Full Text] [Related]
7. Prevention of the Recurrence of Superficial Bladder Cancers: Intravesical Instillation of Bacillus Calmette-guerin Versus Bacillus Calmette-guerin Plus Epirubicin.
Tozawa K; Okamura T; Yamada Y; Hayashi Y; Sasaki S; Kohri K
Asian Pac J Cancer Prev; 2000; 1(3):217-220. PubMed ID: 12718668
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
Yossepowitch O; Eggener SE; Bochner BH; Donat SM; Herr HW; Dalbagni G
J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
[TBL] [Abstract][Full Text] [Related]
9. Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors.
Lüftenegger W; Ackermann DK; Futterlieb A; Kraft R; Minder CE; Nadelhaft P; Studer UE
J Urol; 1996 Feb; 155(2):483-7. PubMed ID: 8558641
[TBL] [Abstract][Full Text] [Related]
10. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
[TBL] [Abstract][Full Text] [Related]
11. Production of tumor necrosis factor by intravesical administration of bacillus Calmette Guérin in patients with superficial bladder cancer.
Kim CI; Shin JS; Kim HI; Lee JM; Kim SJ
Yonsei Med J; 1993 Dec; 34(4):356-64. PubMed ID: 8128741
[TBL] [Abstract][Full Text] [Related]
12. Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome.
Waked R; Choucair J; Chehata N; Haddad E; Saliba G
J Clin Tuberc Other Mycobact Dis; 2020 May; 19():100149. PubMed ID: 32099909
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
[TBL] [Abstract][Full Text] [Related]
14. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
15. [Intravesical instillation of bacillus Calmette-Guerin for superficial bladder carcinoma: study on significance of additional maintenance instillations of bacillus Calmette-Guerin].
Yabusaki N; Komatsu H; Tago K; Yamada Y; Ueno A
Nihon Hinyokika Gakkai Zasshi; 1991 Feb; 82(2):290-6. PubMed ID: 1904120
[TBL] [Abstract][Full Text] [Related]
16. A Case of Epididymo-orchitis after intravesical bacille Calmette-Guérin therapy for superficial bladder carcinoma in a patient with latent tuberculosis infection.
Colomba C; Di Carlo P; Guadagnino G; Siracusa L; Trizzino M; Gioè C; Cascio A
Infect Agent Cancer; 2016; 11():25. PubMed ID: 27257433
[TBL] [Abstract][Full Text] [Related]
17. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
[TBL] [Abstract][Full Text] [Related]
18. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
[TBL] [Abstract][Full Text] [Related]
19. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
[TBL] [Abstract][Full Text] [Related]
20. [A Case Diagnosed as Iatrogenic Vesical Tuberculosis 4 Years after Intravesical Immunotherapy Using Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Carcinoma].
Kudo T; Iwasa N; Maeda S; Mitarai S
Kansenshogaku Zasshi; 2016 Nov; 90(6):809-13. PubMed ID: 30277373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
